Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab in HER-2 Positive Metastatic Colorectal Cancer
NCT07407465Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in colorectal cancer (CRC), sponsored by Gruppo Oncologico Nord Ovest. Started Oct 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07407465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407465.